2O22
Arvinas initiates first registrational study with vepdegestrant
2021
Arvinas partners with Pfizer to co-develop and co-commercialize vepdegestrant
2020
Efficacy proof of concept is achieved for bavdegalutamide and vepdegestrant
2O19
Arvinas PROTAC® degraders, bavdegalutamide and vepdegestrant, enter clinical studies
2O18
Arvinas creates the first blood-brain barrier-crossing PROTAC® protein degrader
2016
Arvinas creates the first oral PROTAC® protein degrader
2O13
Arvinas is founded with the goal to turn protein degraders into patient therapies
2OO1
Arvinas’ founder, Craig Crews, publishes the first paper describing heterobifunctional protein degraders
